Article Text


The role of inhaled corticosteroids in children with asthma
  1. John Price
  1. Department of Child Health, King's College, University of London, UK
  1. Professor J Price, Department of Child Health, King's College Hospital, Denmark Hill, London SE5 8RX, UK email:john.price{at}


Inhaled corticosteroids offer a wide range of anti-inflammatory activity and have consistently proved to be the most effective medication for the control of childhood asthma. The high efficacy of inhaled corticosteroids has led to their use in milder disease and younger children in the hope that permanent changes in lung function and airway remodelling may be prevented. However, evidence has emerged over the past six years that the first of the inhaled corticosteroids to become available, beclomethasone dipropionate, may cause growth deceleration at a dose of 400 μg per day. This is especially apparent in children with mild symptoms. The newest of the inhaled corticosteroids to be developed, fluticasone propionate, is equipotent to older compounds at half the dose and in low doses is superior in efficacy to sodium cromoglycate. Two recent studies have shown that fluticasone propionate 100–200 μg per day does not cause growth suppression in children with mild asthma. The long term outcome for children who wheeze in early life is difficult to predict. For this reason the use of inhaled corticosteroids in very young children is best reserved for those with severe symptoms or a strong family history of asthma, and evidence, from measurement of inflammatory markers, of airway inflammation.

  • asthma
  • inhaled corticosteroids
  • growth velocity
  • wheeze

Statistics from

Inhaled corticosteroids were introduced in 1973 as an alternative to the oral formulation for the treatment of children with moderate or severe asthma.1 Evidence indicates that the frequency of asthma symptoms and the number of exacerbations are reduced, and lung function and the quality of life are improved following treatment with inhaled corticosteroids.1

A total of 23 311 asthma deaths were registered in England and Wales between 1983 and 1995. An observational study over this period of time showed a 6% per year decline in the number of deaths in children aged 5–14 years, which was possibly owing to a greater awareness of the need for prophylactic medication and hospitalisation for exacerbations of asthma.2

Based on the proven advantages of inhaled corticosteroids, international guidelines recommend that low dose (400 μg or less) inhaled corticosteroids be used for the treatment of mild and persistent childhood asthma.3-5 However, concerns remain regarding the long term side effects of inhaled corticosteroids, such as beclomethasone dipropionate, on the hypothalamic–pituitary–adrenal axis and childhood growth rates.6

This paper reviews the evidence of the efficacy of inhaled corticosteroid therapies for the treatment of childhood asthma and the risk of growth suppression as an adverse event.


The increased use of inhaled corticosteroids is based on the superior efficacy of these agents compared with sodium cromoglycate. Although this is well established in adults there are few published studies comparing the efficacy of inhaled corticosteroids with sodium cromoglycate in children. Price and Weller7 compared the efficacy of inhaled fluticasone propionate (50 μg twice daily) with that of sodium cromoglycate (20 mg four times a day) over eight weeks in 225 asthmatic children aged 4–12 years, who had not previously been treated with inhaled corticosteroids or sodium cromoglycate. Although both treatments improved forced expiratory volume (FEV1) and peak expiratory flow (PEF) compared with baseline, fluticasone propionate significantly improved both morning (p = 0.0001) and evening PEF (p = 0.0011), but not FEV1compared with sodium cromoglycate. The effect of fluticasone propionate was apparent after only 1–2 weeks of treatment (fig 1). Fluticasone propionate was more effective than sodium cromoglycate (p < 0.05) in terms of the proportion of symptom free days and nights. Fluticasone propionate also showed a superior safety profile, and thus had a better risk to benefit ratio than sodium cromoglycate in this study. It is necessary to give inhaled steroids twice daily to achieve asthma control, but a once a day regimen is as effective as twice daily when treating stable, mild to moderate asthma in children.8

Figure 1

Comparative efficacy of fluticasone propionate 100 μg/day and sodium cromoglycate 80 mg/day taken for eight weeks in 225 asthmatic children aged 4–12 years. Open and closed circles depict fluticasone propionate and sodium cromoglycate respectively. *p < 0.05; ***p = 0.001. Reprinted by permission of W B Saunders Company.7



Various studies have examined the effect of inhaled budesonide, fluticasone propionate, and beclomethasone dipropionate on short term growth of the lower leg in asthmatic children, assessed by knemometry.

Low dose budesonide does not suppress growth in asthmatic children. Although budesonide (200 μg, 400 μg, and 800 μg daily) dose dependently reduced growth velocity in one study, this only reached statistical significance with the highest dose.910 Wolthers and Pedersen11 reported that neither budesonide 200 μg nor 400 μg daily administered via Turbuhaler reduced growth velocity in 37 asthmatic children. Two further studies confirmed that budesonide 800 μg/day but not 200 μg/day impaired growth.1213 Bisgaard observed a 50% reduction in growth velocity with budesonide 800 μg/day administered for four weeks compared with placebo in 18 toddlers.12

One dose–response study which compared the effects of two doses of fluticasone propionate 200 μg and 400 μg daily (administered via Diskhaler), budesonide 200 μg and 400 μg daily (via Turbuhaler), or placebo on lower leg growth rates in 48 asthmatic children aged 6–12 years, showed that only those children treated with budesonide 400 μg daily had lower growth rates than placebo treated children after two weeks of treatment.14

One study that compared beclomethasone dipropionate 400 μg and 800 μg daily and fluticasone propionate 200 μg daily showed that both doses of beclomethasone dipropionate impaired growth, whereas fluticasone propionate did not.15


Four randomised controlled trials have reported that beclomethasone dipropionate 400 μg/day slows growth velocity by approximately 1–1.5 cm per year.16-19

The first16 compared beclomethasone dipropionate with theophylline in children aged 6–16 years with asthma ranging from mild to moderately severe. Asthma control was better in children treated with inhaled steroid but growth was slower than in those treated with theophylline. The wide age range raises the possibility that age of onset of puberty was a confounding variable.

Doull and colleagues17 noted that 94 children with infrequent wheezing associated with viral infection treated with beclomethasone dipropionate 400 μg daily via Diskhaler for seven months had grown by a mean of 1 cm less than children who received placebo treatment (2.66 v 3.66 cm; p < 0.001). In this study beclomethasone dipropionate had no therapeutic benefit on mild intermittent virus associated wheezing.20 Furthermore, beclomethasone dipropionate treated patients remained significantly shorter than placebo treated patients at the end of the study (4.72 v5.56 cm; p = 0.0004).

Simons18 evaluated the efficacy of beclomethasone dipropionate 400 μg/day, salmeterol 50 μg twice daily, and placebo over one year in 241 children aged 6–14 years with persistent asthma. Beclomethasone dipropionate treated patients grew significantly less (3.96 cm) than those in the placebo (5.04 cm; p = 0.018) and salmeterol (5.4 cm; p = 0.004) groups.

Verberne and colleagues19 compared the effects of long term administration of either salmeterol 100 μg/day or beclomethasone dipropionate 400 μg/day in 67 asthmatic children aged 6–16 years. After one year, asthma control and lung function were better (fig 2) in the beclomethasone dipropionate treated patients, but they had grown significantly less than salmeterol patients (4.7 v 6.1 cm; p = 0.007). Height was also expressed as the height standard deviation score (beclomethasone dipropionate group −0.03v salmeterol group −0.28 at 54 weeks; p = 0.001; fig 3).

Figure 2

Effect of treatment with either beclomethasone dipropionate 400 μg/day (crosses) or salmeterol 100 μg/day (closed squares) for one year on FEV1 in 67 asthmatic children aged 6–16 years. Reproduced with permission.19

Figure 3

Effect of treatment with either beclomethasone dipropionate 400 μg/day (crosses) or salmeterol 100 μg/day (closed squares) for one year on height change in 67 asthmatic children aged 6–16 years. Reproduced with permission.19

In contrast to these studies, Silverstein and colleagues21studied 153 children whose mean age at the onset of asthma was 6 years and who had taken corticosteroids for an average of seven years, and reported that inhaled corticosteroids did not affect the final height attained in adulthood. Corticosteroid treated boys and girls achieved heights of 178.1 cm at 19 years and 166.3 cm at 17 years, respectively, compared with average heights of 179.7 cm and 165.6 cm for boys and girls respectively in those who had not taken corticosteroids. Another study recently reported a similar absence of effect of inhaled corticosteroids on final height.22

There are several possible explanations for this apparent lack of consistency between growth velocity and final height following long term beclomethasone dipropionate treatment.

  • The first possible explanation pertains to the time period during which these children were enrolled—that is, from 1964 to 1983. During this time, glucocorticoid treatment of asthma was changing: in the 1960s and 1970s, low dose oral corticosteroids were only prescribed to patients with severe asthma, whereas inhaled corticosteroids have been commonly prescribed since the 1980s; compared with inhaled therapy, oral steroid treatment is associated with growth impairment.23 McCowan and colleagues24reported that children who had mild to moderate symptoms of asthma grew normally (mean female and male adult heights were 165.6 (6.0) and 179.7 (6.8) cm respectively), while those who had severe symptoms and who were treated with high doses of corticosteroids, were significantly shorter (mean female and male adult heights were 166.3 (6.4) and 178.1 (7.3) cm respectively).

  • Variable compliance and/or non-compliance may be a factor as seen by “growth catch up” when children become symptom free and stop taking their medication. One study of compliance revealed that according to daily diaries, 95% of patients used inhaled corticosteroids as prescribed; however, investigators found the actual use to be 60%, with only approximately 30% of doses taken at the correct time.25

  • A third possible reason may involve the lack of dose reduction once optimum control of asthma is achieved in randomised controlled trials. For example, in the study of Verberne and colleagues,19 the FEV1 in beclomethasone treated patients had improved substantially after three months and many children had become symptom free. In clinical practice, this would be an indication to halve the dose of inhaled steroid.


One study, which compared the effects of fluticasone propionate 100 μg/day with sodium cromoglycate 80 mg/day on growth in asthmatic children over a year, reported similar height and height velocity standard deviations following treatment, indicating that neither fluticasone propionate (6.0 (0.1) cm) nor sodium cromoglycate (6.5 (0.5) cm) caused growth retardation.26

Furthermore, Allen and colleagues23 observed that treatment with fluticasone propionate 100 μg/day or 200 μg/day for one year did not significantly reduce growth rates in 325 asthmatic children compared with placebo. Fluticasone propionate 200 μg/day is at least as effective as beclomethasone dipropionate 400 μg/day in the treatment of mild to moderate childhood asthma. In one study, fluticasone propionate 200 μg/day taken for six weeks improved morning PEF over baseline to a slightly greater extent than beclomethasone dipropionate 400 μg/day (fig 4).27 Rao and colleagues6 compared growth rates in children with moderately severe asthma aged 5–10 years receiving either beclomethasone dipropionate 400 μg/day or fluticasone propionate 200 μg/day. Growth velocity in the children receiving fluticasone propionate (5.75 cm/year) was significantly greater than in the children receiving beclomethasone dipropionate (fig 5).6Likewise, De Benedictis and colleagues28 observed a significantly lower growth velocity in children treated with beclomethasone dipropionate 400 μg/day for a year (4.09 cm/year) compared with those who received fluticasone propionate 400 μg/day (4.09 v 4.99 cm/year; p < 0.001).

Figure 4

Effect of fluticasone propionate 200 μg/day compared with beclomethasone dipropionate 400 μg/day on lung function in asthmatic children over six weeks. Open and hatched columns depict fluticasone propionate and beclomethasone dipropionate respectively. Reprinted with permission from the BMJ Publishing Group.27

Figure 5

Mean growth rate in 23 corticosteroid naïve children with severe asthma aged 5–10 years treated with fluticasone propionate and beclomethasone dipropionate. (Between group difference: 0.81 cm/y; 95% CI: 0.45–1.16 cm/y.) From Rao et al.6


Several cross sectional or short term longitudinal studies which evaluated the effect of inhaled corticosteroids on bone metabolism have indicated that treatment does not affect bone density. One longitudinal study showed that bone density was similar in 51 patients treated with either low (⩽500 μg/day) or high (>800 μg/day) dose budesonide or beclomethasone dipropionate for three years and that bone density remained constant throughout the study.29 However, this study was conducted in adults and too few longitudinal studies have been conducted in asthmatic children to draw any conclusions on the long term effects of inhaled corticosteroids on bone metabolism in children. Two studies in which 83 children with asthma inhaled beclomethasone dipropionate (<300 μg/day) for six or seven months showed that bone mineral density was not altered.3031 Furthermore, corticosteroid administration for 16 months did not alter bone density in 21 children with moderate to severe asthma.32

Inhaled corticosteroids in preschool children

Over the past decade, more than 20 studies have examined the efficacy of inhaled corticosteroids in preschool asthmatic children. Studies in children over the age of 2 years with moderate to severe persistent symptoms have consistently shown a beneficial effect.33 Little or no benefit is seen in those with episodic viral wheeze.34 In children under the age of 2 years, the results of the clinical trials with inhaled steroids have given variable and inconsistent results. Bisgaard and colleagues35 recently showed that inhaled fluticasone propionate via the Babyhaler spacer achieved good control of symptoms in children aged 1–4 years with moderate asthma. Fluticasone propionate 200 μg/day also significantly reduced the number of asthma exacerbations compared with placebo (fig 6). However, the dilemma of which patients to treat remains.

Figure 6

Effect of fluticasone propionate propionate 100 μg/day and 200 μg/day, compared with placebo on the incidence of exacerbations of asthma in children. Reproduced with permission.35

Martinez and colleagues36 conducted a prospective study of wheezing during the first six years of life in a group of over 1000 children. A third of these children developed wheezing illness during the first three years, of which 40% were still wheezing at the age of 6 years and many had developed lung function abnormalities. However, the other 60% had become symptom free. Thus, if all were treated in the first three years with inhaled steroids 60% would be treated unnecessarily. On the other hand, if none were treated the opportunity to prevent lung function abnormalities in some would be lost.

Examination of the risk factors associated with asthma may help to define which children to treat. Parental asthma, particularly if both parents are affected, is a significant risk factor (40%), although it only accounts for 0.3% of the persistent wheezing child population.37 The presence or absence of parental atopy is also a frequently reported risk factor; if one parent is affected the risk is 19% whereas if neither are affected the risk falls to 13%. However, many children who develop persistent wheezing do not have a parental history of asthma or atopy. To date, there are no established guidelines regarding which patients to treat. However, it is logical to treat preschool children who exhibit frequent persistent symptoms, severe exacerbations, or who have clinical evidence of lung hyperinflation between attacks. A lower threshold to introduce inhaled steroid treatment should be applied to those with a personal or family history of atopy or increased concentrations of eosinophil cationic protein.


The data presented within this review show that inhaled corticosteroids effectively manage childhood asthma by improving symptom control and lung function. However, at recommended doses some, but not all, corticosteroids may be associated with growth retardation in asthmatic children.

Many children who experience wheezing during their early childhood outgrow their symptoms. Those who experience severe wheezing are more likely to have persistent symptoms. Thus preschool children who experience frequent exacerbations or who have frequent and persistent or severe wheezing should be treated with inhaled steroids.

Inhaled corticosteroids are recommended for the treatment of persistent asthma of all severities in school age children, but the lowest possible effective dose should be used.3-5 When high doses of inhaled corticosteroids are necessary, the clinical benefits must be balanced against the possibility of growth retardation. Patient growth should be carefully monitored and the dose reduced according to symptom improvement.

Beclomethasone dipropionate at a dose of 400 μg/day may cause growth deceleration, particularly if used in children with mild asthma. On the other hand fluticasone propionate at recommended doses (100–200 μg/day) does not retard growth and is at least as effective as other therapeutic options.


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.